GO:2000417 negative regulation of eosinophil migration: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000417 describes any process that stops, prevents or reduces the frequency, rate or extent of eosinophil migration, a key braking mechanism in allergic inflammation.
• Eosinophil migration is a multi-step process (adhesion, actin polymerization, chemotaxis) that can be inhibited by endogenous factors such as lactoferrin and IL-35.
• The two prostaglandin D2 receptors DP and CRTH2 exert opposing effects on human eosinophil migration, illustrating the balance of positive and negative regulation.
• Semaphorins and their receptors are emerging regulators of eosinophil trafficking and allergic disease, providing new targets for therapeutic intervention.
• Dysregulation of negative regulation of eosinophil migration contributes to allergic rhinitis, eosinophilic asthma, and other eosinophil-driven disorders.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling negative regulation of eosinophil migration.
Description
Eosinophils are granulocytic leukocytes that normally reside in small numbers in the gastrointestinal tract but are rapidly recruited to sites of allergic inflammation and helminth infection. Their migration from the bloodstream into tissues is a tightly controlled process, and the Gene Ontology term GO:2000417, negative regulation of eosinophil migration, captures the biological processes that stop, prevent or reduce this movement. Understanding these inhibitory mechanisms is essential because excessive eosinophil infiltration underlies a wide range of allergic and inflammatory diseases, including allergic rhinitis and eosinophilic asthma. The term encompasses both cell-intrinsic brakes, such as intracellular kinase signaling that restrains actin polymerization, and extracellular cues, such as lactoferrin and IL-35, that directly suppress eosinophil chemotaxis. Recent work has also implicated semaphorins and prostaglandin D2 receptors in tuning eosinophil migration, highlighting the complexity of this regulatory node. For researchers, GO:2000417 provides a structured framework to annotate genes and pathways that dampen eosinophil motility, enabling functional studies with CRISPR-engineered cell models.
negative regulation of eosinophil migration At A Glance
| GO ID | GO:2000417 |
|---|---|
| GO term | negative regulation of eosinophil migration |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents or reduces the frequency, rate or extent of eosinophil migration |
| Related process | Regulation of eosinophil chemotaxis and adhesion |
| Cellular context | Eosinophils, endothelial cells, and tissue microenvironment |
| Disease relevance | Allergic rhinitis, eosinophilic asthma, atopic disorders |
| Research tools | CRISPR knockout, knock-in, overexpression, and chemotaxis assays |
What Is GO:2000417?
According to the QuickGO definition, GO:2000417 (negative regulation of eosinophil migration) refers to any process that stops, prevents or reduces the frequency, rate or extent of eosinophil migration. In other words, it is the collection of molecular and cellular events that put the brakes on the movement of eosinophils, whether by blocking chemokine sensing, inhibiting adhesion, or suppressing the cytoskeletal rearrangements required for locomotion.
Why Is negative regulation of eosinophil migration Important in Cell Biology?
Negative regulation of eosinophil migration is critical for limiting tissue damage during allergic inflammation. Without adequate braking mechanisms, eosinophils accumulate excessively and release cytotoxic granule proteins that injure airway epithelium and other tissues. The process is also relevant to understanding why some individuals with atopic disorders have persistent eosinophilia despite therapy. By identifying the genes and signals that negatively regulate eosinophil migration, researchers can develop targeted strategies to enhance these brakes therapeutically.
• Controls the resolution phase of allergic inflammation by preventing excessive eosinophil tissue infiltration.
• Provides molecular targets for treating eosinophilic asthma and allergic rhinitis.
• Lactoferrin is a natural inhibitor of eosinophil migration, linking innate immunity to eosinophil regulation.
• IL-35 suppresses eosinophil migration and activation, offering a cytokine-based therapeutic avenue.
• Prostaglandin D2 receptors DP and CRTH2 have opposing effects, revealing a tunable checkpoint.
• Semaphorin signaling modulates eosinophil trafficking and allergic disease severity.
• Intracellular kinases regulate actin polymerization, a prerequisite for eosinophil motility.
• Dysregulation of negative regulation contributes to primary atopic disorders.
• CRISPR screens can identify novel negative regulators of eosinophil migration.
• Understanding this process aids in biomarker discovery for eosinophil-driven diseases.
What Happens During negative regulation of eosinophil migration?
Initiation of inhibitory signals
In simple terms: The process begins when external or internal signals tell the eosinophil to stop moving.
Negative regulation of eosinophil migration can be initiated by soluble factors such as lactoferrin, which directly inhibits eosinophil chemotaxis. IL-35 also acts as an inhibitory cytokine that reduces eosinophil migration and activation. These signals engage receptors on the eosinophil surface and trigger intracellular cascades that oppose migratory machinery.
Suppression of actin polymerization
In simple terms: The cell's internal skeleton is prevented from rearranging, which is needed for movement.
Eosinophil migration depends on dynamic actin polymerization, and intracellular kinases regulate this process. Negative regulation involves inhibition of these kinases or activation of opposing phosphatases, leading to reduced actin turnover and impaired leading-edge formation. This step effectively freezes the cell's motility apparatus.
Modulation of chemokine sensing
In simple terms: The cell's ability to smell chemical trails is reduced.
Prostaglandin D2 acts through two receptors, DP and CRTH2, which have opposing roles in human eosinophil migration. Activation of DP may inhibit migration, while CRTH2 promotes it, illustrating how negative regulation can occur at the level of chemokine receptor signaling. Semaphorins also modulate chemokine sensing in allergic diseases.
Inhibition of adhesion and transmigration
In simple terms: The cell is prevented from sticking to blood vessel walls and squeezing through.
IL-35 reduces eosinophil adhesion, a necessary step for transmigration into tissues. By dampening adhesion molecule expression or function, negative regulators block the physical interaction between eosinophils and endothelial cells, thereby reducing tissue infiltration.
Resolution and maintenance of tissue homeostasis
In simple terms: The brakes stay on to keep eosinophil numbers low in tissues.
Persistent negative regulation ensures that eosinophils do not accumulate excessively after an allergic challenge. Defects in this process can lead to chronic eosinophilic inflammation, as seen in eosinophilic asthma where epithelial barrier integrity is impaired. Primary atopic disorders may also involve mutations in genes that normally restrain eosinophil migration.
Key Genes Involved in GO:2000417 negative regulation of eosinophil migration
The following genes and proteins have been experimentally linked to the negative regulation of eosinophil migration or closely related inhibitory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LTF | Lactoferrin inhibits eosinophil migration | Natural inhibitor; potential therapeutic |
| IL35 | Cytokine that suppresses eosinophil migration and activation | Anti-inflammatory cytokine; target for allergic rhinitis |
| PTGDR | DP receptor for prostaglandin D2; may inhibit migration | Opposing roles with CRTH2 in eosinophil migration |
| PTGDR2 | CRTH2 receptor for prostaglandin D2; promotes migration | Counterbalance to DP; drug target |
| SEMA3A | Semaphorin involved in allergic disease modulation | Regulates eosinophil trafficking |
| SEMA4D | Semaphorin implicated in allergic inflammation | Potential regulator of eosinophil migration |
| PLXNA1 | Semaphorin receptor | Mediates semaphorin effects on eosinophils |
| PLXNB1 | Semaphorin receptor | Mediates semaphorin effects on eosinophils |
| NRP1 | Neuropilin co-receptor for semaphorins | Modulates semaphorin signaling in allergy |
| RHO | Small GTPase regulating actin polymerization | Downstream of inhibitory signals |
| ROCK | Rho-associated kinase; regulates actin | Potential target for inhibiting migration |
| PI3K | Phosphoinositide 3-kinase; promotes migration | Inhibition reduces eosinophil motility |
| AKT | Serine/threonine kinase downstream of PI3K | Modulates survival and migration |
| MAPK1 | Mitogen-activated protein kinase | Involved in intracellular signaling |
| MAPK3 | Mitogen-activated protein kinase | Involved in intracellular signaling |
| DSG2 | Desmoglein-2; epithelial barrier integrity | Dysregulation linked to eosinophilic asthma |
| INHBB | Inhibin subunit beta B; TGF-beta signaling | Potential regulator of migration in cancer models |
How Is negative regulation of eosinophil migration Regulated?
Negative regulation of eosinophil migration is itself controlled by a network of cytokines, lipid mediators, and intracellular signaling pathways. IL-35 and lactoferrin act as extracellular brakes, while prostaglandin D2 receptors DP and CRTH2 provide opposing intracellular signals. Semaphorins and their receptors add another layer of regulation in allergic contexts. Intracellular kinases such as PI3K, AKT, and MAPKs modulate the cytoskeletal machinery required for migration, and their inhibition can enhance negative regulation. Dysregulation of these pathways may contribute to primary atopic disorders.
negative regulation of eosinophil migration and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL35 | Allergic rhinitis | Knockout mice or human eosinophil cell line with IL-35 overexpression |
| DSG2 | Eosinophilic asthma | Airway epithelial cell knockout of DSG2 |
| LTF | Allergic inflammation | Lactoferrin-treated eosinophil migration assays |
| PTGDR/PTGDR2 | Eosinophil migration balance | CRISPR knock-in of receptor variants |
| INHBB | Colorectal cancer metastasis | Knockout in cancer cell lines |
Allergic rhinitis
In allergic rhinitis, eosinophil infiltration into nasal mucosa is a hallmark. IL-35 has been shown to reduce eosinophil migration and activation, suggesting that enhancing negative regulation could alleviate symptoms. Defects in endogenous inhibitory pathways may exacerbate disease.
Eosinophilic asthma
Eosinophilic asthma is characterized by airway eosinophilia and epithelial barrier dysfunction. Desmoglein-2 dysregulation impairs epithelial barrier integrity, potentially increasing eosinophil migration into airways. Strategies that boost negative regulation of eosinophil migration could reduce airway inflammation.
Primary atopic disorders
Primary atopic disorders are monogenic conditions with severe allergic inflammation. Rapid genomic sequencing can identify mutations in genes that normally negatively regulate eosinophil migration, providing diagnostic and therapeutic insights.
Cancer and metastasis
Although eosinophils are not the primary focus in cancer, genes such as INHBB have been implicated in liver metastasis of colorectal cancer via TGF-beta signaling and anoikis resistance. This highlights broader roles for migration-regulatory pathways.
From negative regulation of eosinophil migration-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate eosinophil migration? | CRISPR knockout in eosinophil-like cell lines (e.g., HL-60 clone 15) |
| Does a point mutation in gene Y alter inhibitory function? | Point-mutation knock-in via CRISPR |
| Does overexpression of gene Z enhance negative regulation? | CRISPR-mediated overexpression or lentiviral transduction |
| Where is protein X localized during inhibition? | Tagged knock-in with fluorescent protein |
| Which genes are essential for negative regulation? | Genome-wide CRISPR library screening |
| How does gene expression change during inhibition? | RNA-seq and bioinformatics analysis |
How to Study the negative regulation of eosinophil migration Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis | Number of migrated cells | Testing inhibitors of eosinophil migration |
| Microfluidic chemotaxis | Directionality and speed | Real-time analysis of negative regulation |
| Actin polymerization assay | F-actin content | Assessing cytoskeletal inhibition |
| CRISPR knockout screen | Gene essentiality for migration | Discovery of novel negative regulators |
| RNA-seq | Transcriptional changes | Pathway analysis of inhibitory signals |
| Proteomics | Protein expression and modifications | Identifying signaling nodes |
| Flow cytometry | Surface marker expression | Adhesion molecule quantification |
Chemotaxis assays
Transwell or microfluidic chemotaxis assays measure the frequency and rate of eosinophil migration in response to chemoattractants. They are used to test the effects of inhibitory factors such as lactoferrin or IL-35.
Actin polymerization assays
Fluorescence-based actin polymerization assays quantify cytoskeletal rearrangements, a key step in migration. Intracellular kinase inhibitors can be tested to assess negative regulation.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain alters eosinophil migration. Hits are validated in secondary assays.
Transcriptomics and bioinformatics
RNA-seq of eosinophils under inhibitory conditions reveals gene expression changes. Bioinformatics pathway analysis links these changes to GO:2000417.
How CRISPR Can Be Used to Study GO:2000417 negative regulation of eosinophil migration
Knockout
CRISPR knockout of candidate genes in eosinophil-like cell lines can test whether they are required for negative regulation of migration. For example, knocking out PTGDR may reduce the inhibitory effect of prostaglandin D2.
Point Mutation
Introducing disease-associated point mutations into genes such as DSG2 can reveal how specific variants impair negative regulation and contribute to eosinophilic asthma.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-tagged RHO) allows live-cell imaging of cytoskeletal dynamics during inhibition of migration.
Overexpression
CRISPR activation or lentiviral overexpression of genes like IL35 or LTF can enhance negative regulation and serve as proof-of-concept for therapeutic strategies.
How EDITGENE Supports negative regulation of eosinophil migration Research
Researchers studying negative regulation of eosinophil migration-related genes often need to determine whether a candidate gene is causally involved in suppressing eosinophil motility or is merely a bystander. CRISPR-based models provide the gold standard for such causal inference, enabling precise genetic perturbations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of eosinophil migration research.
Frequently Asked Questions About negative regulation of eosinophil migration
What is GO:2000417?
GO:2000417 is the Gene Ontology term for negative regulation of eosinophil migration, defined as any process that stops, prevents or reduces the frequency, rate or extent of eosinophil migration.
What genes are involved in negative regulation of eosinophil migration?
Genes such as LTF, IL35, PTGDR, PTGDR2, SEMA3A, and DSG2 have been implicated in inhibitory pathways controlling eosinophil migration.
How is eosinophil migration negatively regulated?
It can be negatively regulated by extracellular factors like lactoferrin and IL-35, by opposing prostaglandin D2 receptors, and by intracellular inhibition of actin polymerization.
What diseases are associated with defective negative regulation of eosinophil migration?
Allergic rhinitis, eosinophilic asthma, and primary atopic disorders are associated with excessive eosinophil infiltration when negative regulation fails.
What experimental models are used to study negative regulation of eosinophil migration?
Transwell chemotaxis assays, actin polymerization assays, CRISPR knockout cell lines, and genome-wide screens are commonly used.
Can CRISPR be used to study negative regulation of eosinophil migration?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models allow precise dissection of genes controlling eosinophil migration.
What is the role of lactoferrin in eosinophil migration?
Lactoferrin inhibits eosinophil migration, acting as a natural negative regulator.
How does IL-35 affect eosinophils?
IL-35 reduces eosinophil migration, adhesion, and activation, making it a potential therapeutic for allergic rhinitis.
What is the role of prostaglandin D2 receptors in eosinophil migration?
DP and CRTH2 have opposing effects: DP may inhibit migration while CRTH2 promotes it.
Why is negative regulation of eosinophil migration important for drug discovery?
Enhancing these inhibitory pathways could reduce eosinophil-driven tissue damage in asthma and allergies, offering new therapeutic targets.
Conclusion
GO:2000417, negative regulation of eosinophil migration, represents a critical braking system that prevents excessive eosinophil infiltration into tissues. Dysregulation of this process contributes to allergic rhinitis, eosinophilic asthma, and primary atopic disorders. Key molecular players include lactoferrin, IL-35, prostaglandin D2 receptors, and semaphorins, which act through diverse mechanisms to suppress eosinophil motility. CRISPR-based models are indispensable for causally linking genes to this process and for identifying new therapeutic targets. Continued research into the negative regulation of eosinophil migration promises to yield novel strategies for controlling eosinophil-driven diseases.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Bournazou I et al.. 2010. Inhibition of eosinophil migration by lactoferrin.. Immunol Cell Biol 88(2):220-3 PMID: 19918259
- 3. Naito M et al.. 2024. The role of semaphorins in allergic diseases.. Allergol Int 73(1):31-39 PMID: 37635021
- 4. Weston MC et al.. 2008. Role of intracellular kinases in the regulation of equine eosinophil migration and actin polymerization.. J Vet Pharmacol Ther 31(1):31-8 PMID: 18177316
- 5. Zeng Q et al.. 2022. Effect of IL-35 on apoptosis, adhesion, migration, and activation of eosinophils in allergic rhinitis.. Pediatr Allergy Immunol 33(2):e13717 PMID: 34902176
- 6. Yang N et al.. 2026. INHBB promotes liver metastasis of colorectal cancer via regulation of TGF-β/Smad signaling, EMT and anoikis resistance.. Tissue Cell 99:103258 PMID: 41380489
- 7. Yao L et al.. 2026. Desmoglein-2 dysregulation impairs epithelial barrier integrity in eosinophilic asthma.. Respir Res 27(1):71 PMID: 41566510
- 8. Chiba T et al.. 2011. The opposing role of two prostaglandin D2 receptors, DP and CRTH2, in human eosinophil migration.. Ann Allergy Asthma Immunol 106(6):511-7 PMID: 21624751
